Nature子刊：王小龙团队等利用AlphaFold3改造Fanzor系统，实现高效基因编辑

Core Insights - The article discusses the advancements in CRISPR technology, particularly focusing on the Fanzor system, which has shown potential for genome editing in eukaryotic organisms, including mammals [2][3][6]. Group 1: Fanzor System Development - The Fanzor system, discovered by Zhang Feng's team, is a compact RNA-guided DNA cutting enzyme that allows for precise genome editing in eukaryotes, overcoming limitations of traditional CRISPR-Cas systems [2][3]. - The original Fanzor system exhibited low editing efficiency in mammalian cells, which restricted its applications in biomedical research and genetic improvements [2][6]. Group 2: Enhanced Fanzor System - A collaborative research team developed an enhanced version of the Fanzor system, named enNlovFz2, which improved genome editing efficiency by 11 times compared to the wild-type [3][7]. - The enNlovFz2 system was successfully applied in creating mouse models for diseases such as albinism and Duchenne muscular dystrophy (DMD), demonstrating its potential in disease modeling and gene therapy [3][9]. Group 3: Technical Innovations - The research utilized AI-assisted structural predictions and protein engineering to optimize the enNlovFz2 system, expanding its target recognition range significantly [6][7]. - The enNlovFz2 system achieved an insertion/deletion efficiency of 81.2% across 26 target sites in the human genome, comparable to other advanced genome editing tools [7][9]. Group 4: Implications for Future Research - The advancements in the Fanzor system highlight its versatility as a multifunctional toolbox for biological research and therapeutic applications, particularly in gene editing [9][10].